MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F15%3A00078716" target="_blank" >RIV/00209805:_____/15:00078716 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14740/15:00084339 RIV/00179906:_____/15:10316821

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770730/pdf/oncotarget-06-38695.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770730/pdf/oncotarget-06-38695.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.18632/oncotarget.5735" target="_blank" >10.18632/oncotarget.5735</a>

Jazyk výsledku

angličtina

Název v původním jazyce

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab

Popis výsledku v původním jazyce

The aim of our study was to investigate whether microRNAs (miRNAs) could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in patients with RAS wild-type (wt-RAS) metastatic colorectal cancer (mCRC). Historical cohort of 93 patients with mCRC (2006-2009) was included and further divided into exploratory and validation cohorts. MiRNAs expression profiling was performed on the exploratory cohort of 41 wt-KRAS mCRC patients treated with cetuximab to identify miRNAs associated with time to progression (TTP). The validation was performed on two independent cohorts: 28 patients of wt-RAS mCRC treated with cetuximab and 24 patients of wt-RAS mCRC treated with panitumumab. We identified 9 miRNAs with significantly different expression between responders and non-responders to cetuximab therapy (P &lt;= 0.01). These 9 miRNAs were further evaluated in two independent cohorts of patients and miR-31-3p (P &lt; 0.001) and miR-31-5p (P &lt; 0.001) were successfully confirmed as strongly associated with TTP in wt-RAS mCRC patients treated with cetuximab but not panitumumab. When evaluated on the complete cohort of cetuximab patients (N = 69), miR-31-3p (HR, 5.10; 95% CI, 2.52-10.32; P &lt; 0.001) and miR-31-5p (HR, 4.80; 95% CI, 2.50-9.24; P &lt; 0.001) were correlated with TTP on the comparable level of significance. There was no difference in miR-31-5p/3p expression levels in RAS mutated and wild-type tumor samples. MiR-31-5p/3p are promising predictive biomarkers of cetuximab response in wt-RAS mCRC patients.

Název v anglickém jazyce

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab

Popis výsledku anglicky

The aim of our study was to investigate whether microRNAs (miRNAs) could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in patients with RAS wild-type (wt-RAS) metastatic colorectal cancer (mCRC). Historical cohort of 93 patients with mCRC (2006-2009) was included and further divided into exploratory and validation cohorts. MiRNAs expression profiling was performed on the exploratory cohort of 41 wt-KRAS mCRC patients treated with cetuximab to identify miRNAs associated with time to progression (TTP). The validation was performed on two independent cohorts: 28 patients of wt-RAS mCRC treated with cetuximab and 24 patients of wt-RAS mCRC treated with panitumumab. We identified 9 miRNAs with significantly different expression between responders and non-responders to cetuximab therapy (P &lt;= 0.01). These 9 miRNAs were further evaluated in two independent cohorts of patients and miR-31-3p (P &lt; 0.001) and miR-31-5p (P &lt; 0.001) were successfully confirmed as strongly associated with TTP in wt-RAS mCRC patients treated with cetuximab but not panitumumab. When evaluated on the complete cohort of cetuximab patients (N = 69), miR-31-3p (HR, 5.10; 95% CI, 2.52-10.32; P &lt; 0.001) and miR-31-5p (HR, 4.80; 95% CI, 2.50-9.24; P &lt; 0.001) were correlated with TTP on the comparable level of significance. There was no difference in miR-31-5p/3p expression levels in RAS mutated and wild-type tumor samples. MiR-31-5p/3p are promising predictive biomarkers of cetuximab response in wt-RAS mCRC patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/NT13860" target="_blank" >NT13860: Studium signální dráhy EGFR a expresních profilů mikroRNA v predikci odpovědi na cílenou anti-EGFR terapii u pacientů s kolorektálním karcinomem s nemutovanou variantou onkogenu KRAS</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ONCOTARGET

ISSN

1949-2553

e-ISSN

1949-2553

Svazek periodika

6

Číslo periodika v rámci svazku

36

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

38695-38704

Kód UT WoS článku

000366114000021

EID výsledku v databázi Scopus

2-s2.0-84948783085